ITIF - The Information Technology and Innovation Foundation

04/22/2024 | Press release | Distributed by Public on 04/21/2024 22:37

LATAM Health Champions, 2024

LATAM Health Champions, 2024

April 22, 2024

Innovation plays a critical role in improving public health and in overcoming global health challenges. The call for LATAM Health Champions, which ran from February 5 to March 5, 2024, received more than 60 applications proposing innovative health solutions to a wide range of health challenges. Here, the top 20 are highlighted.



Application 1: Fundación Cardiovascular de Colombia (Colombia) 2

Application 2: Montejo Innovation SAS (Colombia) 3

Application 3: AVEDIAN-AUMED SAS (Argentina) 4

Application 4: BIENI-MED, S.A. (Panama)5

Application 5: The Lily Project (Nicaragua)5

Application 6: Fundación Santa Fe de Bogotá (Colombia)6

Application 7: HealthAtom (Chile)7

Application 8: FOODVICA SA de CV (Mexico)8

Application 9: KITSMILE (Colombia)8

Application 10: Instadosis App - Healpty S.A. (Panama)9

Application 11: Universidad de La Sabana (Colombia)10

Application 12: KUMPELS- KUMPELS S.A.S. (Colombia)11

Application 13: Viretec Gestión y Desarrollo SA de CV (Mexico)12

Application 14: Caja Costarricense de Seguro Social (Costa Rica)13

Application 15: Otilia (Argentina)14

Application 16: PILL.AR (Argentina)15

Application 17: TARGETSOFTDECOLOMBIA SAS (Colombia)16

Application 18: Reliv (Ecuador)17

Application 19: Selectivity (Argentina)18

Application 20: Pacifico Salud - SAHSAC (Peru)19


Innovation plays a critical role in improving public health and in overcoming global health challenges, and robust intellectual property (IP) rights play a key role in enabling innovation around the world by providing incentives for innovators to invest research and development (R&D) activities to drive development of health innovations.

Our organizations, the Information Technology & Innovation Foundation (ITIF), the Latin American Federation of the Pharmaceutical Industry (FIFARMA), and Instituto de Prospectiva e Innovacion en Salud (INNOS) have teamed up to launch a competition to identify the most novel and promising health care innovations in South America. Our Call for LATAM Health Champions, which ran from February 5 to March 5, 2024, received more than 60 applications proposing innovative health solutions to a wide range of health challenges. This booklet highlights the top 20 applications that were deemed most groundbreaking.

The different health challenges addressed by these innovations include:

A device for fertility treatments that allows gynaecologists to cheaply and easily perform intrauterine inseminations in their offices, expanding access to fertility treatments.

A tool that makes education on sexual and reproductive health more broadly accessible.

A device that provides pulmonary resuscitation without previous medical training.

An artificial intelligence (AI) monitor that determines the level of anaesthesia depth for patients during surgery.

A tool that allows non-specialized healthcare personnel to stop haemorrhage during childbirth in an easy, affordable, nonsurgical, anaesthesia-free, and painless manner.

A low-cost platform for 3D printing of medications that will improve access to personalized medicine by allowing for individually scaled medication production.

An AI platform that extracts actionable data during the patient journey to support insurers, hospitals, and drug manufacturers, addressing the problem of fragmentation in health systems that can limit the effective use of the large amount of data generated.

Application 1: Fundación Cardiovascular de Colombia (Colombia)

The Cardiovascular Foundation of Colombia (FCV) is one of the most important medical complexes in Colombia and Latin America. It is the first institution in the country accredited by the Joint Commission International (patient safety) and HIMSS Emram 7 (Digital Hospital). The FCV constitutes a health ecosystem that has 13 health business units. One of those units is a Research Center, with recognition at the regional, national, and international levels. To date, it is the Colombian company with the highest number of granted patents in medical technology and is also specialized in the production of medical devices that are marketed throughout the country. FCV works with criteria of excellence, innovation, and social sense to provide patients with the best care.

"SISTEMA DE TELEMONITOREO TELSY"is a portable diagnostic tool used to monitor the vital signs in individuals in a mobile manner, with remote transmission and georeferencing, aimed at integrating these benefits to sense, visualize, transmit, and continuously store the status of a patient's physiological parameters and thereby verify clinical status. The most innovative function of the "Telsy" telemonitoring system is the "TelsyHogar home assistant" monitor that enables sending the patient's sensed data to a remote station that can be viewed through a computer or cell phone with Internet access, using different transmission media.This equipment has earned a patent for the integration of a device that takes vital signs to trace the data from the doctor's interface, and a mobile application that allows bidirectional communication with the patient and/or their caregiver.

In this era of technological disruption, a system like Telsy not only solves healthcare needs in a timely and relevant way but also strengthens the use of information technology as a strategic element in the sector, especially telehealth. It is an ideal complement to the insurance and health service delivery model that allows increasing capacity and resolution in primary and high complexity care, giving continuity to the home management plan, which can be accompanied through this type of medical devices for patient monitoring. This enables the health professional to make safe decisions based on data, not only physiological ones associated with vital signs, but also those associated with disease management, which generally depends to a large extent on self-care measures (i.e., diet, physical activity, and stress management), adherence to medications, and medical management. This is one of the biggest challenges for the growing population of patients with chronic diseases, and solutions like this hope to lead to a reduction of hospitalizations and costs. Likewise, and equally relevant in the impact, is that the patient feels accompanied throughout the care process, since Telsy empowers patients in their care and improves their adherence to treatment, which ultimately reduces health costs for the patient and the system. The invention allows the patient telemonitoring system, based on the synergy between the vital sign monitor, the web platform, and the mobile application, to provide an innovative alternative based on the trust generated between the medical team and the patients.

Application 2: Montejo Innovation SAS (Colombia)

Montejo Innovations (MI) is a design and development company focused on contributing to the social and health sectors. Its products combine technical and technological cutting-edge solutions for current local and global challenges.

Montejo Innovations created AIR, a system that uses a ventilation mask with a CO2 sensor, a software-operated self-regulated oxygen source, and dedicated cervical support to provide pulmonary resuscitation without previous medical training and without mouth-to-mouth contact. AIR is a complete system contained in a rigid protection case that can be placed in airports, schools, recreational areas, and swimming pools, among others. It stands out from others on the market for two main reasons: Currently, some knowledge or training is required to carry out resuscitation manoeuvrers. The waiting time for emergency assistance can be considerably long. The defibrillators one encounters now are not easily accessible at different public points.

AIR is characterized by its innovative system that uses a ventilation mask with a CO2 sensor, a self-regulated oxygen source operated by software, and a cervical support. It is designed to be used by anyone without previous medical training and is used in conjunction and simultaneously with the Automatic External Defibrillator (AED). Its final use is the same as that of the AED, that is, in public places with high foot traffic globally. MI's vision is to make this device widely available and accessible to increase survival chances in critical situations worldwide. Additionally, the company has received a Colombian patent and is in the process of requesting patents in Brazil, China, Europe, Japan, Mexico, the United States, and beyond.

Application 3: AVEDIAN-AUMED SAS (Argentina)

AVEDIAN has developed an AI-based platform that extracts actionable data during the patient journey, allowing: 1) Insurers to improve prevention and risk management and implement result-based contracting and payment models to their providers; 2) Hospitals to reduce clinical variability and achieve greater efficiency and patient safety; and 3) Drug manufacturers to improve market access by implementing shared risk agreements with insurers. The innovative solution developed by AVEDIAN addresses the problem of fragmentation in health systems, which limits the effective use of the large amount of data generated. Approximately 30 percent of data worldwide is health data, but its potential is not fully utilized. The consequences are evident. In health insurers, up to 40 percent of care spending can be optimized through evidence-based risk management and efficiency control in providers. On the other hand, in hospitals, intuitive patient management generates variability, inefficiency, and avoidable costs, which ultimately impact insurers.

Additionally, new high-priced medicines, such as biologics, are also overloading insurers' budgets, generating frictions in their market access. The AVEDIAN platform uses AI to extract actionable data along the "patient journey," thus allowing significant improvements at different levels. AVEDIAN allows more precise identification of risk factors in insured populations so that clinicians can implement effective and personalized preventive strategies, which in turn reduces costs associated with potential treatments and hospitalizations. Thanks to information processed using AI, insurers can implement outcome-based contracting models with the DRG (Diagnosis Related Groups) methodology. This means that providers are compensated for the quality and effectiveness of care provided (rather than the quantity of services provided). This incentivizes patient-centered care. AVEDIAN is one of the three companies worldwide with proprietary DRG algorithms. Moreover, AVEDIAN addresses the intuitive management of patients by providing detailed, descriptive, and predictive information about each case treated. This is achieved by leveraging the use of DRG algorithms and performing clinical benchmarking of indicators, which allows for more informed decisions and standardization of clinical practice through guides and protocols. The optimization of processes based on DRG methodology also allows for the automation of data collection and detection of areas for improvement in patient safety indicators.

The competitive advantage of the AVEDIAN solution lies in its unique ability to integrate, through interoperability and international standards, all the crucial information necessary to obtain actionable data in insurance companies, hospitals, and drug manufacturers. This comprehensive approach translates into significant and differentiating benefits compared to other solutions available in the market. AVEDIAN helps drug manufacturers better understand the market environment. Through the extraction of actionable data, drug developers can adapt product launch strategies and establish risk-sharing agreements with insurers facilitating access of medicines, especially those of high cost, as it better aligns interests with needs and priorities of health systems. By understanding the specific challenges of insurers and hospitals, drug manufacturers can adjust their commercial strategies and prices to ensure better access and acceptance in the market. In summary, the AVEDIAN solution not only addresses current deficiencies in health data management, but also proposes concrete AI-based improvements in prevention, efficiency, and market access.

Application 4: BIENI-MED, S.A. (Panama)

BIENI-MED, S.A. is a Panamanian private company that has developed an innovative mobile application aiming to transform healthcare management. With the overall goal of building an integrated healthcare ecosystem, Bieni focuses on simplifying access to medical records, improving service delivery efficiency, and promoting active user participation by fostering a culture of prevention and well-being. In the heart of Bieni beats an ambitious goal: to transform healthcare management in Panama. The company's goal is to build an integrated healthcare ecosystem, weaving a digital network that simplifies access to medical records, improves efficiency in the delivery of healthcare services, and, most importantly, encourages active participation of each user in managing their well-being.

Bieni stands out for several innovative differential elements that position it as a unique solution compared to other alternatives in the digital health market. The Bieni proposal is not limited to medical record management; it goes beyond by building a comprehensive health ecosystem. This holistic approach connects healthcare professionals, users, and other stakeholders, creating a collaborative network that improves coordination and efficiency of healthcare. It encourages active participation of individuals in managing their well-being by providing educational tools, personalized reminders, and a direct communication channel. This allows users to take a proactive role in their health. The solution stands out for its focus on user experience.

Simplifying access to medical records is a priority, thus making information easily accessible for users and healthcare professionals. This accessibility significantly contributes to more informed decision-making. Bieni not only seeks immediate solutions but also has a long-term vision to contribute to the advancement and sustainability of the Panamanian healthcare system. It aspires to be a leader in the digital health revolution and to be internationally recognized for its positive impact. Together, these elements differentiate Bieni-Med by offering not only a technological solution, but a complete transformation in the way health is approached and managed. This makes a significant difference compared to other market alternatives, consolidating Bieni-Med as a unique proposal that integrates with existing digitized systems, focusing on the construction of a comprehensive health ecosystem and the active well-being of each individual.

Application 5: The Lily Project (Nicaragua)

The Lily Project has been working for over seven years using an innovative methodology that combines in-person assistance with virtual education on sexual and reproductive health, as well as screening for cervical cancer prevention in rural areas of Nicaragua. The initiative has examined over 23,000 women and performed cryotherapy treatments on more than 1,500 women. The Lily Project's founders felt that something was missing in this space, so in 2021, they launched a new program called Chava, a mobile application for sexual and reproductive education that provides access to information, tools, and comprehensive, personalized, and confidential care for anyone who identifies or has experiences as a Latin American woman or girl.

Chava, a mobile application for sexual and reproductive health, enables the end user to use it for free, confidentially, and personalized based on their needs. In this way, the organization aims to close the equity gap that exists between communities and countries. The app can be downloaded on the Play Store. While there are many Femtech companies offering some type of innovative product to improve women's lives, Chava is focused on young women aged 15 to 24, as this is the age group most engaged digitally and at the highest risk of unwanted pregnancy. Additionally, the global Femtech market is expected to grow to $10.1 billion by 2028, but only 1 percent of this is distributed to Latin America. The company's market is Spanish speakers, and the entire user experience is based on Latin culture, as many of the available apps offering sexual health services are translated, losing cultural relevance.

At least 70 percent of students lack access to comprehensive sexual health education. Geographical barriers, low levels of sexual health knowledge due to stigma, and lack of accurate information play a significant role in misinformation and the perpetuation of taboos. Guilt, shame, and isolation surrounding their experiences permeate the lives of women and girls. There is an equity gap, where socially and economically marginalized women are disproportionately affected by unequal access to education and basic services. Thus, the team at The Lily Project aims to raise awareness about the importance of a healthy life, significantly contributing to reproductive health issues. Additionally, their goal is to reduce teenage pregnancies (which represent 15 percent of all pregnancies in individuals under 20 years old) and contribute to keeping girls in schools (37 percent of dropouts are attributed to economic disparities and gender inequality). Finally, the organization aims to serve as a guide in girls' health and amplify the voices of each one of them, improving the quality of life for women and girls, based on experience and informed decision-making about their bodies and health.

Application 6: Fundación Santa Fe de Bogotá (Colombia)

The Fundación Santa Fe de Bogotá is a leading institution in the health innovation ecosystem in Colombia and Latin America. Its main function is focused on the research and development of new therapies, medical technologies, and advanced procedures. Through medical research programs, collaborations with universities and the industry, and technology transfer, the foundation promotes the creation and application of innovative solutions to improve medical care and patient outcomes. Additionally, it serves as a major center for the education and training of health professionals, offering continuing education programs and research opportunities. The institution promotes a culture of innovation in the health sector, fostering collaboration, creativity, and the adoption of new technologies and approaches to address current and future health challenges. In short, the Santa Fe de Bogotá Foundation plays a crucial role in advancing medicine and improving healthcare in the region through research, education, and the promotion of health innovation.

"Clip de mama" is an innovative medical device specifically designed to optimize the accuracy and effectiveness of breast cancer monitoring. This device is projected to be used with low-cost hospital supplies, making it accessible in diverse medical environments. Its functionality focuses on a tumor marker for breast biopsies, equipped with a universal applicator that allows precise placement in the intramammary tissue. One of the key features of this device is to allow the improvement of the location of tumors, cysts, or abnormal tissues through imaging equipment. This is crucial in post-biopsy breast monitoring, where the accuracy in identifying the lesion is fundamental to determine the appropriate treatment plan. The device design includes an opening system that facilitates its fixation to the intramammary tissue, which ensures secure and stable placement during medical procedures. In addition, its configuration is optimized for easy identification through imaging equipment, which improves the efficiency of the diagnostic process and contributes to patient safety. This innovative approach improves access by offering a more economical alternative and timely treatment of breast cancer, which improves clinical outcomes. Also, by reducing associated costs, it relieves the financial burden on health systems, allowing for more efficient resource allocation and potentially broadening medical insurance coverage.

The "Clip de mama" presents significant potential positive impacts for the detection and treatment of breast cancer and other medical diseases. It has the potential to significantly improve accessibility, reduce costs, and broaden the scope to multiple medical conditions, offering benefits at both individual and systemic levels in healthcare. By providing a more economical alternative to current devices, this technology could improve patient access to tumor markers for breast biopsies, which would increase opportunities for timely breast cancer treatment. Also, its ability to migrate to other types of biopsies, such as of the liver and lung, suggests a broader impact on the diagnosis and treatment of various medical conditions, which could represent a significant advancement in healthcare in general. This technology has the potential to significantly improve healthcare by increasing access to tests and expanding its application to various medical conditions, which would benefit numerous patients at the national and international level.

Application 7: HealthAtom (Chile)

HealthAtom is the leading company in the Healthtech software as a service (SaaS) industry in Latin America. Its goal is to improve the quality of and access to healthcare for people through the creation of its digital ecosystem that connects healthcare providers and other stakeholders in the field, allowing efficiency, traceability, control, and regulatory compliance for all parties. With its solutions, Dentalink and Medilink, as SaaS verticals, it is a catalyst for change with more than 13,000 healthcare providers and 60,000 users who use their software daily in 23 countries, generating a volume of more than 45 million effective appointments on their platforms. With its fintech, Gerty, it brings financial benefits to patients, being the point of connection that facilitates secure, fast, and 100 percent-reliable access for users. Currently, it has more than 200 collaborators and is leading the digital development of the healthcare industry in Latin America.

Dentalink was created with a mission to improve the quality of and access to healthcare for individuals by freeing up administrative time for dental clinics. This solution, with over 14 years on the market, has revolutionized the management of thousands of dental clinics, providing a single platform for access to patient medical history information, intelligent reporting, treatments, patient loyalty, email marketing, task automation, patient financing, and much more. The company's software is unique in Latin America, with certifications such as Health Insurance Portability and Accountability Act (HIPPA) compliance and ISO 27001. In addition, clients give Dentalink a net promoter score (NPS) of 75, making it as a world-class software.

Dentalink addresses the entire patient journey, providing features for appointment scheduling, clinical records, reporting, business analysis, patient loyalty, and even financing treatment for patients. Its goal is to improve the quality of and access to healthcare for people by freeing up administrative time for dental clinics, addressing challenges such as: three out of four patients do not start clinical treatment due to lack of income and that dentists who work with paper can spend three hours a day on administrative tasks, time that can be invested in seeing more patients if management tasks are digitized. Eighty-five percent of Latin American dentists claim that the biggest challenge for a dental clinic is hypercompetition and market adaptation; and for 92 percent of dentists, the patient experience is important when deciding to continue treatment at a clinic.With over 70,000 healthcare professionals using Dentalink's software, it represents a solution that truly supports making the lives of healthcare professionals easier, giving them the opportunity to focus on what's important: their patients' health. Additionally, HealthAtom's financial solutions (i.e., online credits, dental insurance), will bridge the healthcare gap, providing access to a potential 230 million people in Latin America.

Application 8: FOODVICA SA de CV (Mexico)

FOODVICA's mission is to innovate and provide support, guidance, and advice for the development of products of great social importance and impact. FOODVICA developed Formulación para revertir las cataratas, a new non-surgical treatment that's potentially applicable to patients at any stage of cataract maturation, through an ophthalmic composition, at a lower cost, and with greater possibility of access to people who suffer from this condition. Cataracts are the leading cause of reversible blindness in the world and affect at least 100 million people; factors such as aging, ultraviolet radiation, diabetes, and other diseases cause its appearance. The only existing treatment is surgery, with the complexity and costs that this implies, and it is also applied only to people with an advanced degree of the disease. This prevents addressing it from its earliest stages of development. Currently, the patent protects a synergistic combination of compounds, whose results demonstrate a reversal of grade 4 cataracts to grade 1 in a rat model, and has already been granted in Mexico and presented in primary markets internationally.

Cataracts affect 100 million people worldwide. In Mexico, it affects 3 million people and it is estimated that each year there will be 140,000 new cases. It is a disease that is often linked to a lack of resources and access to health services, which is why it's "almost four times more common in poor and illiterate people living in marginalized and rural areas than in rich neighborhoods," according to the Pan American Health Organization (PAHO). The sick, by not treating it, can lose their vision and be affected economically, as it prevents them from being productive. The invention is applicable to people at any degree of cataract maturation, through an ophthalmic composition, at a lower cost, and with a greater possibility of access. As surgery is not accessible to the entire population due to costs and the need for an infrastructure that is only available in large cities, Formulación para revertir las cataratas can help solve this international problem. It provides a non-surgical solution using nanotechnology, a formulation that has been shown to reverse cataracts in animal models in a short time. The solution is much cheaper than surgery, more accessible, and provides for a far better patient experience.

Application 9: KITSMILE (Colombia)

KITSMILE was founded in 2014, inspired by the case of Laura, a 5-year-old girl with cerebral palsy who lived in Maya Cundinamarca, a rural town where there was not adequate access to healthcare. KITSMILE designed the first gym to support rehabilitation at home, unique in the world, called "GymSmile." The gym has a patent and enables children, youth, and adults to exercise, eat, study, rest, and perform different activities daily to improve their condition, going from not having rehabilitation to having an at home tool that supports their process 24/7. The "GymSmile" adjusts to the growth of children from 2- to 12-years-old or from 50cm to 1.50cm in its Junior version and up to 1.80 cm in its adult version, making it evolve with the child's growth. In addition, it has organic shapes and colors that make it look like a toy, so it generates a lot of acceptance among regular children. The fabric of "GymSmile" will adapt specifically to the conditions of children with disabilities, as it withstands high temperatures, liquids and fluids, and has a system that allows the air to run and children to not stick to them, eliminating bedsores from the materials traditionally used in the market.

The innovative solution offered by GymSmile has the potential to generate a significantly positive impact on society, especially on the lives of people with cerebral palsy or physical disabilities, as well as their families and the healthcare system. In Colombia, there are 300,000 children with cerebral palsy, of which 70 percent are like Laura. Cerebral palsy affects approximately 17 million people worldwide, representing a significant global prevalence. In terms of incidence, analysts estimate that between 1.5 and 4 out of every 1,000 babies are born with cerebral palsy, making it the most common movement disorder in children. By providing a tool that facilitates a wide range of daily exercises and activities in the comfort of the home, GymSmile can substantially improve users' quality of life, allowing them to participate in daily activities with greater independence and comfort. Similarly, by having access to a rehabilitation tool at home, users can perform therapies more frequently and consistently, which is crucial for progress in conditions such as cerebral palsy. This is particularly important in areas where access to specialized rehabilitation services is limited or non-existent. By focusing on key areas such as head control, postural alignment, and stretching exercises, GymSmile can help prevent secondary complications associated with cerebral palsy and other physical disabilities, which in turn can decrease the need for additional medical interventions.

Families live far from specialized centers, and their primary caregivers are often single mothers who have to give up their jobs to take care of their children. These families face the highest rates of extreme poverty in Colombia. Without access to frequent rehabilitation, children's conditions worsen, leading to other disabilities resulting from inadequate care and, primarily, lack of opportunity. By facilitating rehabilitation at home, GymSmile can help reduce the costs associated with professional rehabilitation treatments, transportation to therapy centers, and the acquisition of multiple assistive devices as the child grows or the user's needs change. Allowing users and their families to take a more active role in the rehabilitation process empowers individuals, fostering a sense of autonomy and control over their own well-being. GymSmile can help foster greater social inclusion of people with disabilities, by improving mobility and the ability to participate in everyday activities, thus contributing to a more inclusive society that is aware of the needs of all of its members. As a patented and unique solution, GymSmile sets a precedent for innovation in the field of rehabilitation and healthcare, encouraging other companies and organizations to develop equally innovative and effective solutions.

Application 10: Instadosis App - Healpty S.A. (Panama)

Microentrepreneurs contact Healpty S.A. and they help them open pharmacies, while also introducing the company's software (Instadosis) into their pharmacies and charging a monthly fee for it. Instadosis is an exclusive app for healthcare professionals that is capable of instantly calculating medication dosages and interactions. It assists healthcare professionals (doctors and pharmacists) in making better decisions regarding the use of medications, minimizing malpractice. It notifies contraindications in cases of renal and hepatic insufficiency, pregnancy, and lactation. It allows for automatic calculations of dosage and medication interactions, all with just one click. The doctor adjusts the patient's values: weight, age, sex, renal and hepatic insufficiency, and stage of pregnancy (by trimester, month, or week). As the doctor adds medications, the app calculates the dosages and displays alerts for interactions and contraindications on the screen. The doctor evaluates alternatives, adds and removes medications, and assists in making decisions. No other app in the world can make this task so easy. The app also includes the best-classified medications compared to other apps worldwide. It categorizes them by generic name, brand name, laboratory, and pathology, and soon, by supplier. It is like a medication dictionary that also provides instant dosage and interaction calculations.

Instadosis is the only app in the world that, in a single step, is capable of instantly calculating medication doses based on the patient's weight and age. It provides alerts for medication interactions, alerts for drug interactions, recommendations when the patient has liver or kidney insufficiency, or if they are pregnant. The app automatically performs all the analysis and presents it on the screen for the doctor to make decisions. In other apps on the market, medication information is presented in a generic and generalized way, while Instadosis presents it in a specific way. For example, in other apps, medication information is presented as a long text that needs to be read and then calculated. In Instadosis, the user adjusts the weight and age, and the app automatically calculates the dose. In other apps, it can take up to an hour or more because one has to read the text, analyze it, and make the calculations, while Instadosis presents all the calculations in less than a second.

Healthcare professionals have lacked a tool that allows them to efficiently, quickly, and safely access information about medications. This tool serves as a reference for making medical decisions. Healthcare professionals need to consult data such as interactions, dosages, medication concentrations, maximum permitted dosages, indications, and contraindications. Many medication errors are made due to the fast-paced nature of the work. The expected impact is that it reduces the time a doctor takes to search for answers to their questions on the Internet, thereby decreasing their workload. It also minimizes medication errors and helps patients improve their pharmacotherapy.

Application 11: Universidad de La Sabana (Colombia)

The University of La Sabana is a higher education institution that, as part of its mission, engages in teaching, research, and social outreach activities through its undergraduate and graduate programs, including cross-sectional and longitudinal studies for the healthcare sector and clinical trials in partnership with the University of La Sabana Clinic. As a result of several of these R&D efforts, iAMed emerged as a spin-off initiative. Its purpose within the healthcare innovation ecosystem is to offer medical solutions to public and private entities in the healthcare and education sectors based on Industry 4.0 technologies, supported by knowledge and R&D processes.

Knockout is a depth of anaesthesia monitor which acquires and processes signals from electroencephalography, electrocardiography, and non-invasive blood pressure, and with the help of an artificial neural network determines the level of anaesthesia depth with a diagnostic accuracy of 90.55 percent on average, with outstanding performance in detecting awake patients (99 percent) and patients under deep anaesthesia (93 percent). Additionally, the system uses artificial neural networks to support decision-making regarding medication dosages by the anaesthesiologist. The development allows the patient to receive the appropriate dose of anaesthesia and reduces the likelihood of intraoperative awakenings, which have long-term psychological consequences such as post-traumatic stress disorder and depression. Additionally, these can cause medical-legal problems for the attending anaesthesiologist. Being awake during surgery and being unable to do anything about is the worst nightmare for a patient. Patients who wake up during surgery describe a range of sensations, including suffocation, paralysis, and pain. That's why the use of an efficient depth of anaesthesia monitor can lead to an improvement in the quality of health services received by the patient, reducing the likelihood of intraoperative awakening and its psychological impact, as well as allowing hospital resources to be optimized for the benefit of society.

Most of the devices that are direct competitors to Knockout do not have adequate performance and lack full confidence from their users. This is reflected in evidence that around 5 percent of people may wake up on the operating table, and possibly many more, which accounts for approximately 50 percent of related complications. In that sense, the solution developed by the team at Universidad de La Sabana demonstrates better performance since it not only acquires signals from electroencephalography (central nervous system) but also from electrocardiography and blood pressure (autonomic nervous system), allowing for a more comprehensive assessment of the patient's consciousness under anaesthesia. By reducing the number of intraoperative awakenings, Knockout can reduce costs and resource utilization times (e.g., operating room, equipment, human resources), and patient recovery time, as well as a reduction in complications associated with general anaesthesia. The decrease in costs has been quantified between 10 percent and 20 percent in terms of operating room use, equipment, human resources, and complications associated with the procedure. All of this contributes to improving patient safety and well-being and leads to savings in the healthcare system.

Application 12: KUMPELS- KUMPELS S.A.S. (Colombia)

Kumpels' role in the health innovation ecosystem is twofold: on one hand, it develops innovative technological solutions to improve patient safety and efficiency in medical care. On the other hand, it acts as a facilitator and co-creator in the health community, sharing knowledge and experience to drive innovation in the sector and develop new solutions. Kumpels is actively involved in events, acceleration programs, and strategic alliances to promote the exchange of ideas and foster collaboration among diverse actors in the health ecosystem. As a result, it contributes to the advancement of healthcare in Latin America by offering practical and scalable solutions that address the real challenges of the health system and promote greater access, efficiency, and safety in healthcare.

Kumpels Pharma, a technological platform designed to optimize clinical management and prevent medication errors, is a comprehensive tool that addresses key challenges in healthcare, including prescription, dispensing, administration, and monitoring of medications in hospitalized patients. Kumpels Pharma is a Clinical Decision Support System (CDSS) that first performs a multivariate analysis to determine the patients at greatest risk and prioritize them for pharmaceutical care, allowing health professionals to focus on patients in greatest need of intervention. Secondly, it provides comprehensive tracking of medications from initial prescription to patient administration. This includes automatic generation of pharmacotherapeutic profiles from the patient's electronic medical record information, ensuring a comprehensive view of the pharmacotherapy of each and every individual. Finally, Kumpels Pharma facilitates the automatic detection of risk alerts associated with potential medication errors, such as interactions and medication duplications, allowing for timely interventions to prevent adverse events and improve quality of care.

A distinctive feature of Kumpels Pharma is its ability to integrate with existing hospital information systems through an application programming interface (API) and international interoperability standards. This integration ensures real-time updating of patient data and eliminates the need to reprocess or transcribe information, improving efficiency and reducing the risk of errors. In terms of scalability, Kumpels Pharma is designed to adapt to the needs of different health institutions, from small clinics to large hospitals. Its modular architecture and focus on interoperability ensure seamless implementation and the ability to grow as demand increases. The implementation of Kumpels Pharma can significantly improve the safety and quality of medical care for patients. By providing detailed, real-time tracking of medications, the platform helps prevent medication errors, ensuring proper administration of treatments and safe use of medicine.

Furthermore, by optimizing medication-management processes, Kumpels Pharma can help reduce healthcare costs and improve the operational efficiency of health institutions. This frees up financial resources that can be reinvested in improving healthcare in general and in acquiring more advanced technologies and treatments. It is estimated that solutions like Kumpels Pharma can lead to savings of about $2 million per hospital per year. In addition, Kumpels Pharma has the potential to promote equity and accessibility in health care by ensuring all patients receive adequate and timely treatment, regardless of their geographical location or socioeconomic situation. In summary, Kumpels' innovative solution in the health sector not only addresses specific problems related to medication management, but also drives digital transformation in healthcare by improving patient safety, operational efficiency, and quality of care, and contributes to a reduction in non-quality overruns.

Application 13: Viretec Gestión y Desarrollo SA de CV (Mexico)

The Lifeclip project represents a radical solution based on the integration of an innovative, affordable, safe, and user-friendly method and medical device, which allows non-specialized healthcare personnel (nurses/midwives) to stop bleeding in an easy, affordable, nonsurgical, anaesthesia-free, and painless manner. This is achieved by locating and blocking the main blood supply to the uterus through clamping, with specific pressure control that eliminates the risk of uterine perforation and allows for immediate blood flow blockage and restoration. This enables the use of any other maneuverer in the protocol and, if necessary, facilitates the transfer of the patient for proper care.

In the treatment of women with obstetric hemorrhage, the existing alternatives share the same paradigm: the application of pressure on the uterus and its placental bed. This is done either externally using the abdominal component of the non-pneumatic shock suit, internally with intrauterine packing using textiles such as gauze, or by placing intrauterine hydrostatic balloons, which are expensive and require specialized skills for placement. LifeClip represents a disruptive solution in this landscape, being a medical device that, through temporary occlusion of the main artery that supplies the uterus with the greatest blood flow, reduces the volume of bleeding and directly contributes to decreasing complications derived from obstetric hemorrhage, thus saving the lives of mothers in labor. This system is based on the integration of an innovative device supported by Zea's methodological training process, which enables its immediate implementation by healthcare personnel. Unlike current medical care for obstetric hemorrhage, which relies on a single paradigm of using a tamponade balloon to stop bleeding and saturate the uterus, LifeClip modifies this approach by using two perfectly designed clips. These clips block the blood flow with the necessary pressure to stop bleeding without damaging the tissue of the uterine arteries, allowing for immediate restoration of blood flow upon removal.

A significant advantage of LifeClip is that any healthcare personnel, not necessarily specialized, can place the clips and save the patient's life in a simple and easy manner, without the need for surgery, anaesthesia, or pain. Although there are currently alternatives for managing women with obstetric hemorrhage, the current procedures are prohibitively expensive and require specialization, thus turning the current solution into another problem. Viremed S.A.P.I. de C.V.'s project, LifeClip, is based on a profitable business model that aims to reduce the indicator of maternal death at the national and international levels. This is achieved through a comprehensive solution, based on an innovative, cost-effective, safe, and user-friendly medical method and device that can be implemented by non-specialized personnel.It also addresses the significant social implications of leaving a family without a maternal figure. In many cases, the mother is the head of the family, and her absence can have devastating consequences. Through the dissemination of their method and the mass production of their low-cost devices, the company aspires to ensure an effective presence in all regions of the world where complications from obstetric hemorrhage may arise. Viremed S.A.P.I. de C.V. seeks to equip trained individuals with rescue kits that enable effective treatment of complications resulting from this issue, thus significantly contributing to the reduction of maternal mortality and the preservation of family unity globally.

Application 14: Caja Costarricense de Seguro Social (Costa Rica)

The Costa Rican Social Security Fund (CCSS) plays a fundamental role in the health innovation ecosystem in Costa Rica. Its main function is to provide health services to the population, guaranteeing universal and equitable access to medical care. In the context of health innovation, the CCSS performs various important roles including allocating resources to fund medical research and health innovation projects, and evaluating and adopting new medical technologies and innovative treatments that can improve the quality of medical care and health outcomes for the population. The CCSS plays an important role in promoting clinical best practices and quality standards in healthcare.

Type 2 diabetes mellitus (DM2) is a highly prevalent chronic disease in Costa Rica, with a significant impact on public health and the economy. Early detection and prevention are crucial to avoid serious complications and improve the quality of life of the population. The team created a machine learning model for the prediction of the incidence of type II diabetes mellitus for the attended population using data from Costa Rica to help identify individuals at higher risk of developing the disease. It consists of the development of a model with high sensitivity to predict the "Diabetes" class, based on the Random Forest algorithm, with an accuracy of 75 percent and sensitivity of 81 percent. This model predicts in the first instance whether the evaluated person is at risk of developing type 2 diabetes mellitus or not, and in patients at risk, it also classifies them as low, medium, or high risk based on the obtained percentage. Additionally, risk alert outputs are generated in the digital record, risk distribution maps by region, gender, and age of individuals, which serve for decision-making and definition of individual and collective strategies for public health in Costa Rica, with potential to be tested in the region. The solution will be specifically designed for the Costa Rican population, taking into account genetic, demographic, and lifestyle factors that are relevant to this particular population. This will allow for greater accuracy in predictions and recommendations, as they will be tailored to the unique characteristics of Costa Ricans.

The impact of this solution on the problem is significant. The solution allows for the identification of individuals at higher risk of developing type 2 diabetes mellitus before symptoms appear. This facilitates the implementation of preventive strategies and lifestyle changes that can help reduce or delay the development of the disease. By preventing or delaying the development of type 2 diabetes mellitus, the solution contributes to reducing complications associated with this disease, such as cardiovascular diseases, neuropathies, and vision problems. This improves the quality of life for patients and reduces the physical and emotional burden for them and their families. Additionally, by identifying and addressing the risk of type 2 diabetes mellitus early on, the solution helps reduce costs associated with the long-term treatment and management of the disease. This frees up resources that can be directed toward other areas of healthcare, thus improving the overall efficiency of the healthcare system. As it is specifically designed for the Costa Rican population, the solution takes into account existing health disparities and can help address them more effectively. This promotes equity in access to health care and helps improve health outcomes within Costa Rican society.

Application 15: Otilia (Argentina)

The fundamental role of Otilia in the health innovation ecosystem is to provide comprehensive and personalized solutions to address the specific needs of maternity and reproductive health. Through its AI platform, Otilia offers immediate responses and expert guidance to expecting parents, as well as access to online specialists at any time. Otilia's focus on humanizing technology and personalizing services make it a prominent player in the field of maternal and reproductive health, significantly contributing to innovation and well-being in this field. Otilia O.'s platform goes beyond conventional prenatal and postnatal programs. Otilia O. offers a comprehensive approach that combines advanced AI-driven tools with compassionate guidance, ensuring that every aspect of the maternal journey is met with understanding, empowerment, and care. Through this platform, families are not just accessing information; they are connecting with a community that understands their joys, fears, and uncertainties. The organization also personalizes its services to meet the unique needs of everyone, providing tailored support that addresses everything from physical health to emotional well-being.

By leveraging the power of technology, Otilia O. can offer immersive experiences through virtual and augmented reality, allowing future parents to visualize and prepare for the road ahead in an informative and emotionally resonant way. It's about bridging the gap between the digital world and the human experience, creating a space where technology serves as a conduit for empathy, understanding, and support. In summary, the solution goes beyond providing information; it's about creating a nurturing and empowering environment that helps families navigate the complexities of pregnancy, childbirth, and beyond with confidence and resilience. It's about harnessing the latest advances in technology to enhance the human experience, foster connections, and empower people to embrace the transformative journey of parenthood with joy and anticipation. Unlike alternatives such as BabyCenter, Peanut, and Mindfulness Mom, Otilia O. recognizes and tailors its services to the unique needs of each user, offering complete and specific support for every stage of the maternal process. This customization extends across the company's wide range of services and features, including social connection, expert advice, and emotional care. Otilia O. goes further by integrating social connections with expert advice and an integrated agenda.

Otilia O. addresses the critical and widespread need faced by over 3 billion individuals with reproductive intentions worldwide (i.e., motherhood). First, by providing easy and personalized access to reliable information and emotional support, the platform has the power to improve the health and well-being of both mothers and babies. By reducing anxiety and stress associated with pregnancy and postpartum, Otilia O. can help prevent maternal and neonatal health complications, resulting in safer deliveries and healthier babies. Additionally, by offering a virtual community where pregnant individuals can connect, share experiences, and provide mutual support, Otilia O. has the potential to foster a sense of belonging and solidarity among mothers, contributing to greater social cohesion and a stronger support network. This virtual community can also be an invaluable resource for those pregnant individuals who feel isolated or lonely during their pregnancy or postpartum, providing them with a safe and supportive space where they can find comfort and camaraderie. Otilia O. has the potential to reduce maternal health disparities and improve health outcomes for all pregnant individuals, regardless of their geographic location, socioeconomic status, or access to traditional medical care.

Application 16: PILL.AR (Argentina)

PILL.AR is developing a technological platform for 3D printing of medications based on a printing method patented by their entrepreneurial group, registered under the name MESO-PP®, which stands for Melting Solidification Printing Process. This method enables the decentralized production of customized solid pharmaceutical forms (SPFs). The goal is to provide a low-cost technology that will improve access to personalized medicine by allowing for the establishment of a personalized and individually scaled medication production facility at each point of patient care, offering the same quality as traditional laboratories. The main advantage of this proposal is the ability to adjust doses, create palatable solid oral forms for children, combine multiple agents (drugs, vitamins, and nutraceuticals) into a single tablet, and even incorporate technology for patient monitoring. The use of this platform, consisting of the printer, cartridges, and specially designed digital files for each ink (understood as ink: drug + excipients), allows for the automated production of medication batches, independent of the operator (saving time and reducing interindividual variability) and the place of use.

MESO-PP is a simple, flexible, and cost-effective method applicable to small batches of medication manufacturing. It can be adapted to special patient groups and offers multiple advantages over other 3D printing methods focused on decentralized drug production. The current model of the pharmaceutical industry is adapted to standardized production of large batches of medications. This model is obsolete in terms of manufacturing flexibility and is very costly and complex (in terms of modifications to formulation, equipment, and/or processes) to adapt production to the particular needs of small groups of patients. Compounding pharmacies, which are few in number, are the only alternative to adjust medications to the individual needs of the patient (dose, sex, age, genetics, allergies, etc.). However, the processes are manual and require experience and specialized training, leading to significant interpersonal and inter-institutional variability, which is reflected in the quality of the resulting medication. The solution proposed by PILL.AR is to use 3D printing (I3D) to produce medications in pharmacies and patient care points. This technology allows for the creation of solid structures differentiated in size and shape, combining materials of different nature. By simply modifying the ink and/or the file containing the specifications for printing, it is possible to create differentiated solid dosage forms (SDF).

PILL.AR aims to establish decentralized drug production, which can be installed in places where even the presence of pharmacy professionals is limited. The ease of use of the technology can enable even pharmacies without experience in formulation to start offering personalized medications. In this sense, the federalization and territorial reach of this service could be two additional impacts that PILL.AR can offer with its development. On the other hand, there are orphan drugs that cater to a demand from a population small enough that no laboratory is interested in incorporating them into their production line. Through PILL.AR's technology, public production laboratories could meet this demand without compromising the traditional production line. The PILL.AR technology will print medications on the same primary packaging that will be delivered to patients. As a first measure, the use of the technology will possibly avoid the use of secondary packaging that accompanies blisters. On the other hand, by dispensing individualized presentations tailored to the patient's therapy, the waste associated with excess tablets often generated by the standardization of commercial presentations (adapting the number of solid dosage forms to average therapies) is reduced. In these cases, perhaps out of 10 tablets per blister, only 8 are taken, and the remaining 2 must be discarded.

Application 17: TARGETSOFTDECOLOMBIA SAS (Colombia)

TARGETSOFTDECOLOMBIA SAS is a software company specialized in the Healthtech sector. It offers a cloud solution to support management and diagnostics in pathology laboratories, CX cytology, molecular biology, hematooncology, and other areas of oncological diagnosis. It is structured on three main pillars, patient traceability, sample traceability, and result traceability. As the main axis, the focus is on patient care opportunity. QHORTE is used by more than 30 institutions in both the public and private sectors in Colombia, Mexico, the Dominican Republic, and Venezuela. It was awarded as the best success case in health software and the best business model at the 2022 Ingenio Awards. The team were the first application in Colombia to have deployed a cloud-based cancer diagnosis solution, first in 2010 from dedicated cloud servers and later from 2014 on AWS Amazon, becoming a scalable solution, allowing specialists to work collaboratively and omnipresently, with little or no investment in infrastructure.

The second leading cause of cancer death in women in Colombia is cervical cancer, which is considered a public health problem because it is preventable. The team at TARGETSOFTDECOLOMBIA SAS developed the first version called EVAHPV, which evolved to cover all areas of cancer diagnosis, including histology, hematooncology, molecular biology, and flow cytometry, among others, becoming what is now known as "QHORTE," a solution for supporting cancer diagnosis. Guiding and providing support to professionals in laboratories of low, medium, and high complexity. This has led to a reduction in the time required to deliver the diagnostic result or conclusion and has reduced the gap in early detection for cases of present malignancy. QHORTE exposes in its indicators the agreement of the study, which compares the result of the first reading of a cervicouterine cytology vs. the result of confirmation or quality control, showing false negatives. QHORTE seeks to standardize diagnosis within the framework of capturing quality data, so its scope includes diagnosis of ICD-10 and ICD-0 associated with the variables of the high-cost account. It includes controls for timeliness and quality between each of the processes within the workflow. QHORTE has an integration layer to interoperate with electronic medical record systems using HL7 FHIR, an integration layer to operate with electronic billing systems, and an integration layer for communication with biomedical equipment and printers.

Diagnosing cancer is a race for life, and the impact of the solution is directly related to the timely delivery of quality diagnosis to the patient. TARGETSOFTDECOLOMBIA SAS promotes a culture around data quality so that more and more participants (laboratories using QHORTE) deliver data related to cancer, and have regional and national observatories that study cancer behavior in the country, providing information for the structuring of early detection programs. QHORTE is the ally of cancer diagnostic laboratories to optimize the time in delivering the diagnosis, taking into account quality controls, audits, and follow-up at each stage of the process. QHORTE, in addition to being accessible from anywhere with an Internet connection, provides the possibility for small laboratories to make use of Industry 4.0 technologies. QHORTE has created a network of allies to standardize diagnosis, good practices, and support scientific laboratory R&D.

Application 18: Reliv (Ecuador)

Reliv positions itself as an agent driving digital transformation in the healthcare sector by providing innovative technological tools and solutions that enhance the efficiency, accessibility, and quality of medical care. As part of this innovation ecosystem, Reliv is committed to developing disruptive technologies, fostering collaboration, and empowering patients. The team continuously works on the development of new technological solutions that address the current and future needs of the healthcare sector, from comprehensive hospital systems to mobile applications for patients. The company believes in the importance of collaboration among different actors in the healthcare sector, including physicians, hospitals, pharmacies, laboratories, and insurers. They also recognize the importance of empowering patients in managing their own health. Therefore, the company's solutions are designed to improve access to medical information, facilitate communication with healthcare providers, and promote greater patient engagement and participation in their care process.

The solution offered by Reliv stands out for several innovative differentiating elements compared to other alternatives available in the market. Reliv has created a complete and integrated ecosystem that spans from hospital systems to mobile applications for patients. This integration ensures a seamless experience for all stakeholders involved in the healthcare process. Traditionally, healthcare systems have been fragmented, making coordination between different healthcare providers difficult and potentially resulting in a less efficient and coherent patient experience. Reliv addresses this issue by offering an integrated ecosystem that connects doctors, hospitals, pharmacies, laboratories, and insurers in a unified platform. The digitalization of doctors, hospitals, and healthcare processes is fundamental in Reliv's proposal. This not only streamlines administrative procedures but also enables better coordination among different healthcare services and more personalized care for patients. Reliv prioritizes patient convenience and access by offering services such as online scheduling, mobile medical consultation, and the ability to complete the entire healthcare journey, from consultation to medication acquisition, in one place.

Reliv's solution differs from other alternatives in the market by offering a comprehensive, patient-centered, and digitized approach to healthcare, along with effective collaboration with other stakeholders in the healthcare sector. This enables a more complete, convenient, and efficient experience for all involved in the health care process. Furthermore, Reliv's solution overcomes physical or financial barriers to accessing health care by offering services such as virtual medical consultations, online scheduling, and discounts on medications, making health care more accessible and convenient for everyone. The impact of Reliv's solution on these issues is significant. By providing an integrated ecosystem and easy access to medical information, Reliv improves the coordination and quality of health care, resulting in a smoother and more satisfying patient experience. Furthermore, by eliminating barriers to accessing health care, Reliv helps ensure that everyone can receive the care they need, regardless of their geographical location or financial situation. Reliv has the potential to fundamentally transform the way health care is delivered and accessed, improving the health and well-being of people worldwide.

Application 19: Selectivity (Argentina)

Currently, more than 100 million couples face the harsh reality of infertility, and unfortunately, 75 percent of them lack access to adequate treatments. To address this concerning situation, the team at Selectivity have created a patented technology that revolutionizes accessibility to fertility treatments. Selectivity's first medical device allows any gynaecologist to perform intrauterine inseminations (IUI) directly from their office, thus democratizing access to these procedures. In addition, the company has introduced a second device, called DAiO, that offers couples or single women the ability to carry out an IUI autonomously, in the comfort of their home. This innovation not only expands access but also optimizes the process by significantly reducing costs and time. By improving the effectiveness of treatments, the company aims to ensure positive results without compromising the emotional burden that seeking fertility entails. With these solutions, Selectivity aspires to provide hope and options to those facing this challenge, significantly transforming the fertility landscape globally.

The pioneering solution applied to the health sector focuses on two revolutionary devices for fertility treatments. The first, a sperm selection device, uses a patented biomimetic membrane and microfluidic channels with unique dimensions and shapes. This allows gynaecologists to perform intrauterine inseminations in their offices, opening a previously inaccessible market without depending on laboratories. This technology, easy to use, fast and with superior performance compared to current techniques, eliminates the need for sophisticated equipment, avoids traditional manipulations and does not require the presence of highly specialized professionals, simplifying the procedure. The second solution arises from the ability to select sperm in any environment, without the need for control as in a laboratory. This is achieved through the microfluidic technology explained earlier, which allowed the company to develop the first device, globally, for intrauterine insemination to perform IUI outside of clinics and in the comfort of people's homes, reducing times and costs. This innovation encompasses a comprehensive selection and insemination system in a single device, designed to be easily used by any woman (or couple) who needs it. It also reduces the stress associated with infertility and improves the quality of life of those affected.

Currently, couples facing difficulties in conceiving are forced to make appointments at unfamiliar, remote fertility clinics after more than 12 months of attempts, which carries a significant emotional burden. Selectivity's first solution, the sperm selection device, changes this scenario by allowing the couple to continue being cared for by their trusted gynaecologist in their own city, reducing the anguish and anxiety associated with travel and tight deadlines. In addition, it provides professionals in gynaecology with the opportunity to offer a new service to their patients, strengthening the doctor-patient bond and reducing costs and emotional burdens. The second solution, which is a home IUI device, goes a step further by allowing people to face these difficulties from the comfort of their own home. This product, available on digital platforms or pharmacies, gives women the autonomy to follow a personalized treatment, adapted to their own times and desires. This innovative proposal seeks to positively impact the lives of those going through these difficulties, providing affordable and accessible options, and allowing the repetition of the treatment according to the needs and desires of the woman or couple.

Application 20: Pacifico Salud - SAHSAC (Peru)

Pacifico Salud is one of the most important health care companies in Peru, providing both health care services and insurance coverage. The team created T-Sana, a web solution that consolidates the main services necessary for a person to address their low-complexity health issues end-to-end. It offers services such as virtual triage, medical care through teleconsultation, purchase of medications, and referral for cases of higher complexity (to the SANNA network). It is targeted toward the market of uninsured individuals who currently address such problems informally.

It provides the possibility of receiving triage 24/7 and wherever the patient is from any device, and the ability to receive alerts when the doctor who will attend to the patient is ready to assist. The doctor will add the products to a patient's shopping cart as part of preparing the prescription, so the patient won't have to look for them. Patients are able to purchase the products for their treatment with just a few clicks from the same platform. If the patient wishes to continue care through laboratory tests or consultations, they can do so thanks to Pacifico Salud's assistance line, which helps refer patients to the most convenient place within the SANNA network.

T-Sana aims to help the more than 30 million Peruvians who do not have private health insurance to avoid relying on self-medication or alternative solutions, thereby reducing the likelihood of incurring higher expenses and time due to poor care, or even risking their lives. It addresses the issue of self-medication and the use of alternative solutions for addressing low-complexity health problems.

APPENDIX: spanish Language Applications

To see all applications in full, refer to the PDF,
pages 31-157.


ITIF wishes to thank INNOS and FIFARMA for their collaboration in producing this report.

About the Author

Stephen Ezell is vice president for global innovation policy at ITIF and director of ITIF's Center for Life Sciences Innovation. He leads the Global Trade and Innovation Policy Alliance. His areas of expertise include science and technology policy, international competitiveness, trade, and manufacturing. Stephen is the coauthor of Innovating in a Service-Driven Economy: Insights, Application, and Practice (Palgrave McMillan, 2015), and Innovation Economics: The Race for Global Advantage (Yale 2012).

Sandra Barbosu, PhD, is senior policy manager in the Economics of Biopharmaceutical Innovation at ITIF's Center for Life Sciences Innovation. Her research focuses on the economics of innovation, particularly the role of emerging technologies in health care. Sandra is also adjunct professor at New York University's Tandon School of Engineering. She holds a PhD in Strategic Management from the Rotman School of Management at the University of Toronto, and an MSc in Precision Cancer Medicine from the University of Oxford.

Natalie Khoo is policy fellow at ITIF's Center for Life Sciences Innovation. Natalie is currently pursuing a BSc (Honors) of Global and Public Health Sciences at King's College London, and during 2023-2024, she is on a year-abroad program in Washington, D.C., through a partnership with Cornell University.

About ITIF

The Information Technology and Innovation Foundation (ITIF) is an independent 501(c)(3) nonprofit, nonpartisan research and educational institute that has been recognized repeatedly as the world's leading think tank for science and technology policy. Its mission is to formulate, evaluate, and promote policy solutions that accelerate innovation and boost productivity to spur growth, opportunity, and progress. For more information, visit